The Genomic Services Market was valued at USD 6.3 billion in 2023 and is projected to reach USD 17.5 billion by 2032, expanding at a robust compound annual growth rate (CAGR) of 11.8% during the forecast period 2024–2032. Rising demand for precision medicine, technological advancements like next-generation sequencing (NGS), and increased government initiatives to accelerate genomic research are fueling this dynamic market growth.
Growth Drivers Accelerating the Genomic Services Market
The primary growth catalyst for the genomic services market is the increasing application of NGS technology in both clinical and research settings. NGS enables rapid sequencing of entire genomes, delivering high-throughput, cost-effective results with exceptional accuracy. Its growing adoption in diagnostic labs, particularly for oncology and rare genetic conditions, has transformed patient care delivery and opened new clinical pathways.
Furthermore, rising funding from government agencies for genomics-based research has substantially contributed to the market’s momentum. Institutions such as the U.S. National Institutes of Health (NIH) and similar entities across Europe and Asia-Pacific are heavily investing in genome analysis initiatives. The global surge in personalized medicine and pharmacogenomics has further propelled the use of genomic services in tailoring therapies to individual genetic profiles, increasing treatment effectiveness and minimizing adverse drug reactions.
Get a Free Sample Report of Genomics Services Market @ https://www.snsinsider.com/sample-request/2873
Market Segmentation Analysis
By Service Type
The genomic services market is segmented into RNA sequencing, epigenomics services, genotyping, next-generation sequencing, and others. Among these, the next-generation sequencing (NGS) segment dominated in 2023 with a 34.5% market share. This is largely due to its wide clinical application and favorable reimbursement landscape. Collaborations like GeneDx and Pediatrix Medical Group’s NGS integration into neonatal intensive care units (NICUs) illustrate the real-world impact of this technology.
Meanwhile, the genotyping segment is forecasted to grow at the fastest pace. It is increasingly used across pharmacogenomics, agricultural biotechnology, and animal genetics. Its growing role in personalized medicine and genome-wide association studies highlights its importance in advancing genomic healthcare solutions.
By Technology
Among technologies, Polymerase Chain Reaction (PCR) held the largest share in 2023 at 35.9%. PCR continues to be a staple in genomic diagnostics due to its role in infectious disease detection, especially during the COVID-19 pandemic. However, NGS is anticipated to be the fastest-growing technology, given its scalability, speed, and versatility.
By Application
In 2023, the research segment led the market with a 40.1% share, supported by increasing global investments in disease-specific genomic studies. For example, Washington University’s ChromoSeq study exemplifies how genomics is becoming integral to academic and translational research.
The diagnostics segment is also witnessing significant expansion. Rapid genomic testing is becoming essential for early cancer detection and genetic disorder screening. Ongoing partnerships between diagnostic companies and genomics service providers are helping to commercialize cutting-edge testing solutions worldwide.
By End-User
The largest end-user in 2023 was research institutes, accounting for 38.4% of market revenue. The establishment of genome research hubs, such as Indonesia’s National Integrated Center for Genomic and Tropical Biodiversity, reflects a growing global emphasis on academic and applied genomic science.
Meanwhile, healthcare facilities and diagnostic centers are expected to register the highest CAGR over the forecast period. This is attributed to increased deployment of genomic diagnostics for disease screening and prenatal analysis. Pharmaceutical and biotechnological companies are also expanding their footprint via strategic collaborations with genomics service providers to enhance their genomic research pipelines.
Regional Insights
In 2023, North America led the genomic services market with an estimated valuation of USD 3.23 billion. High healthcare expenditure, robust genomic infrastructure, and supportive reimbursement frameworks in the U.S. are key factors driving growth. Initiatives like the CDC’s national viral genomics consortium underscore the region’s leadership in genomic surveillance and pandemic preparedness.
Europe is rapidly catching up, thanks to government-backed precision medicine programs. In April 2021, the UK government allocated over USD 51 million toward genomics and data-driven healthcare solutions. Simultaneously, Asia-Pacific nations like Singapore are advancing large-scale genome research through national strategies, like its National Precision Medicine Program Phase 2.
Latin America and the Middle East & Africa are emerging markets in the genomic services landscape, with increasing investment in cancer genomics and strategic governmental initiatives supporting scientific advancement.
Buy a Single-User PDF of Genomics Services Market Analysis & Outlook Report 2024-2873 @ https://www.snsinsider.com/checkout/2873
Recent Developments in the Genomic Services Market
October 2024: Dovetail Genomics launched a Certified Service Provider Program, aimed at standardizing quality among partner labs and expanding access to advanced genomic analysis.
March 2024: Azenta Life Sciences inaugurated its GENEWIZ Multiomics and Synthesis Solutions lab in Oxford, UK, boosting genomic research capabilities in Europe.
November 2023: Fabric Genomics, in partnership with DNAnexus and Oxford Nanopore Technologies, set up CLIA/CAP-certified labs in NICUs for infant genomic testing.
July 2023: Eremid Genomic Services integrated PacBio’s Revio platform for high-accuracy HiFi sequencing, enhancing its genomics and bioinformatics portfolio.
Key Companies in the Genomic Services Market
Leading players shaping the genomic services market landscape include:
Thermo Fisher Scientific, Inc.
Illumina, Inc.
BGI Genomics
Agilent Technologies
23andMe, Inc.
Bio-Rad Laboratories, Inc.
QIAGEN N.V.
Myriad Genetics, Inc.
Oxford Nanopore Technologies
Quest Diagnostics
Pacific Biosciences of California, Inc.
Eurofins Scientific
Roche Diagnostics
Eppendorf AG
Color Genomics
GE Healthcare
Danaher Corporation
These companies are investing heavily in R&D, forging partnerships, and developing scalable platforms that support both clinical diagnostics and scientific innovation.
Conclusion
With the rising importance of precision medicine, rapid advances in sequencing technologies, and growing public-private investment, the genomic services market is poised for exceptional growth through 2032. Stakeholders across healthcare, academia, and biotech must strategically align with emerging genomic innovations to remain competitive in this transformative industry.
Read Our Other Report
Women’s Health Therapeutics Market
About Us:
SNS Insider is one of the leading market research and consulting agencies that dominates the market research industry globally. Our company’s aim is to give clients the knowledge they require in order to function in changing circumstances. In order to give you current, accurate market data, consumer insights, and opinions so that you can make decisions with confidence, we employ a variety of techniques, including surveys, video talks, and focus groups around the world.
Contact Us:
Jagney Dave – Vice President of Client Engagement
Phone: +1-315 636 4242 (US) | +44- 20 3290 5010 (UK)
Email: [email protected]
